TerminatedPhase 3NCT00799773
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
Studying Congenital thrombotic thrombocytopenic purpura
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Carelon Research
- Principal Investigator
- Susan F. Assmann, PhDNew England Research Institutes, Inc.
- Intervention
- Rituximab(drug)
- Enrollment
- 3 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2009 – 2010
Study locations (23)
- University of Alabama, Birmingham, Birmingham, Alabama, United States
- Emory University, Atlanta, Georgia, United States
- University of Iowa, Iowa City, Iowa, United States
- Tulane University Health Sciences Center, New Orleans, Louisiana, United States
- University of Maryland Medical Center, Baltimore, Maryland, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Children's Hospital Boston, Boston, Massachusetts, United States
- New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States
- University of North Carolina Hospitals, Chapel Hill, North Carolina, United States
- Duke University Medical Center, Durham, North Carolina, United States
- University Hospital Cleveland, Cleveland, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- +8 more locations on ClinicalTrials.gov
Collaborators
National Heart, Lung, and Blood Institute (NHLBI) · Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00799773 on ClinicalTrials.govOther trials for Congenital thrombotic thrombocytopenic purpura
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07513948Daratumumab in Immune-mediated Thrombotic Thrombocytopenic PurpuraFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGNCT06441578A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic PurpuraTakeda
- RECRUITINGNCT01257269Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)Insel Gruppe AG, University Hospital Bern
See all trials for Congenital thrombotic thrombocytopenic purpura →